Can medication help us combat Alzheimer’s disease?

Aducanumab is a newly approved drug for Alzheimer’s disease with the potential to reduce amyloid-beta plaque buildup in the brain. There are other medications being studied to see if they can reduce amyloid-beta, such as a monoclonal antibody that targets amyloid-beta before it forms plaques, and a monoclonal antibody that takes aim at plaque that has already formed. Other experimental approaches try to prevent tau tangles in brain cells, reduce brain inflammation, or reduce the amount of amyloid-beta that is produced.